Study guide
9.2 Lutheran and Other Blood Group Systems
Scientist in Blood Banking, BB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB
2 Donors and Collection
2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations
3 Processing, Storage, and Component QC
3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control
4 Blood Components
4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors
5 Blood Group Genetics and Transfusion Role
5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence
6 ABO and Lewis Systems
6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System
7 Rh System
7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance
8 Kell, Duffy, Kidd, and MNS
8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System
9 Additional Systems and Antigens
9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens
10 Immunology Foundations
10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties
11 Physiology, Hemostasis, Cytopenias, and Transplantation
11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation
12 Hemolytic Disease of the Fetus and Newborn
12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention
13 Routine Serologic Testing
13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing
14 Antibody Identification
14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps
15 Reagents and Special Techniques
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods
16 Serologic QA and Special Reagents
16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence
17 Indications and Component Therapy
17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy
18 Adverse Effects of Transfusion
18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases
19 Apheresis, Administration, and Patient Blood Management
19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management
20 Laboratory Operations
20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation
9.2 Lutheran and Other Blood Group Systems
Key Takeaways Explain This Topic AI
Lua is low-prevalence (~8%) and Lub is high-prevalence (~99.8%); anti-Lub is more often clinically significant than anti-Lua.
Lutheran typing and antibodies are often mixed-field. Lutheran is an IgSF glycoprotein: trypsin and 0.2 M DTT weaken it, but DTT destroys Kell more completely.
Dominant In(Lu) is a KLF1 suppressor that silences Lutheran and also weakens P1, In(b), and AnWj; recessive true Lu-null can make anti-Lu3.
Other systems are clustered by clinical significance and enzyme/DTT behavior, not memorized antigen by antigen: Diego and Colton are usually honored; Ch/Rg and Knops are HTLA.
Ch/Rg are adsorbed C4, neutralized by plasma; LW is confused with D but is DTT-sensitive and strong on cord cells regardless of D type.
Last updated: August 2026
9.2 Lutheran and Other Blood Group Systems
Quick Answer: Lua is low-prevalence; Lub is high-prevalence. Anti-Lub is the Lutheran antibody that matters. Lutheran reactions are often mixed-field . The carrier is an IgSF glycoprotein: trypsin and 0.2 M DTT weaken Lutheran, whereas DTT destroys Kell more completely . In(Lu) is a dominant KLF1 suppressor that silences Lutheran (and weakens P1, In(b), AnWj). Other II.B.11 systems are a cluster table — Diego, Yt, Xg, Scianna, Dombrock, Colton, LW, Ch/Rg, Knops, Indian, OK, Raph, JMH, IGHM, FORS — sorted by clinical significance, enzymes, and DTT , not by encyclopedia entries.
The June 9, 2026 outline gives Lutheran its own line ( II.B.10 ) and then dumps every remaining named system into II.B.11 . The exam is not asking you to recite every Scianna antigen. It is asking whether you can tell anti-Lub from anti-K , anti-LW from anti-D , and anti-Ch from anti-k .
Lutheran antigens and antibodies
LU (ISBT 005) encodes an immunoglobulin-superfamily adhesion molecule (CD239, B-CAM). The two antigens you must know are Lua (LU1) and Lub (LU2) .
Lua is low-prevalence (~8% of people of European ancestry; lower in some other groups).
Lub is high-prevalence (~99.8%). Almost every panel cell is Lu(b+).
Lu(a+b+) is the ordinary heterozygote. Lu(a−b+) is the common type. Lu(a+b−) is uncommon. Lu(a−b−) is rare and is not one genotype — see In(Lu) below.
Anti-Lua is often naturally occurring, IgM or IgG, and usually not clinically significant . It is famous for mixed-field agglutination that looks like a subgroup or a chimera if you are not expecting Lutheran. Anti-Lub is more often immune IgG and is more significant than anti-Lua: mild delayed HTR is reported; HDFN is rare because Lutheran antigens are poorly developed on cord cells . That last fact is the HDFN trap — do not manage anti-Lub like anti-K just because both are high-prevalence IgG antibodies.
Lutheran antibodies may react at room temperature, 37 °C, or AHG. They often look weaker than Kell or Kidd of the same “3+” reputation. Do not discard a Lutheran ID because the reactions are mixed-field or only 1+.
Mixed-field, trypsin, and DTT — Lutheran versus Kell
Two bench habits separate Lutheran from Kell:
Mixed-field is a Lutheran signature (especially Lua). Kell is not a mixed-field system.
0.2 M DTT (and AET) destroys Kell antigens completely because Kell is packed with disulfide bonds. Lutheran is only moderately DTT-sensitive — reactions weaken, they do not always vanish. Trypsin (and α-chymotrypsin) destroys or markedly weakens Lutheran ; Kell is enzyme-resistant (ficin/papain do not strip K/k).
If an unidentified high-prevalence antibody disappears completely after 0.2 M DTT, think Kell (or Yt, Do, JMH, LW) before Lutheran. If it is mixed-field, trypsin-fragile, and only softened by DTT, think Lutheran . Lutheran is IgSF ; Kell is a zinc endopeptidase. The biochemistry is why the DTT tubes disagree.
0.01 M DTT is a different test: it distinguishes IgM from IgG in serum, not Lutheran from Kell on cells. Do not mix the two DTT concentrations on an item.
Three ways to type Lu(a−b−)
In(Lu) , the dominant inhibitor of Lutheran , is a KLF1 (EKLF) transcription-factor variant. It is not a silent LU gene. The red cell types Lu(a−b−) but carries trace Lutheran antigen, so these people do not make anti-Lu3. In(Lu) also weakens P1, In(b), AnWj (CD44-related), and sometimes Knops and I . A “Lu(a−b−), P1-weak, In(b−)” donor is In(Lu) until proven otherwise.
Recessive true Lutheran-null is two silent LU alleles. Those cells lack Lutheran completely and the person can make anti-Lu3 , which behaves as an antibody to a high-prevalence Lutheran antigen. X-linked XS2 is the rare third Lu(a−b−) mechanism (GATA1-related). Recessive null and XS2 do not suppress P1 and In(b) the way In(Lu) does. Phenotype the rest of the membrane before you call the genotype.
Other systems — cluster, do not memorize a textbook
II.B.11 is a sorting problem. Use carrier protein, enzyme/DTT behavior, and whether you honor the antibody.
System Carrier / note Clinical significance Enzymes 0.2 M DTT
Diego (DI) Band 3 (SLC4A1). Dia enriched in South American Indigenous and East Asian people; Dib high-prevalence. Wra (low-prevalence) also lives on Band 3 Anti-Dia and anti-Wra can cause HDFN / HTR Resistant Resistant
Cartwright (YT) Acetylcholinesterase. Yta high-prevalence, Ytb low Anti-Yta variable — often insignificant, occasionally delayed HTR Resistant Destroyed
Xg X-linked Xga (more common in females ~89% than males ~66%) Usually not significant Destroyed Resistant
Scianna (SC) ERMAP. Sc1 high, Sc2 low Rare antibodies; treat as potentially significant if 37 °C / AHG Resistant Resistant
Dombrock (DO) ART4, GPI-linked . Doa/Dob; Hy, Gya, Joa high-prevalence Can cause HTR ; serologic typing is hard — molecular common Variable / weakened Destroyed (GPI)
Colton (CO) Aquaporin-1 . Coa ~99.8% Anti-Coa clinically significant Enhanced Resistant
LW ICAM-4. Stronger on D+ adult cells ; cord cells strongly LW+ regardless of D Usually mild; the exam trap is confusing it with anti-D Resistant Destroyed
Chido/Rodgers Adsorbed C4 (C4B = Ch, C4A = Rg) HTLA, not significant ; neutralized by plasma Destroyed Resistant
Knops (KN) CR1 (CD35) . Kna, McCa, Sla, Yka HTLA, not significant ; weaker in high complement turnover Weakened Weakened
Indian (IN) CD44. Inb high-prevalence; Ina more often South Asian Usually not significant; In(Lu) weakens Inb Destroyed Destroyed
- OK Basigin (CD147). Oka high-prevalence Rare anti-Oka; honor if 37 °C Resistant Resistant
- Raph CD151 (MER2) Rare Variable Variable
JMH Semaphorin 7A, GPI . High-prevalence Often auto in elderly , HTLA-like, usually insignificant Weakened Destroyed (GPI)
IGHM Named rare/other system on the BB list Antibodies uncommon — read the stem’s 37 °C pattern ; do not invent a carrier story Stem-defined Stem-defined
FORS GBGT1 makes FORS1 (Gb5) on the globoside pathway Rare; ABO discrepancy with some anti-B reagents; most people have naturally occurring anti-FORS1 Carbohydrate (enzyme-enhanced) Resistant
LW versus D is the single most-tested “other system” discrimination. Anti-LW reacts more strongly with D+ than D− adult cells, so it looks like anti-D. Two tools break the tie: DTT-treated D+ cells lose LW and keep D , and cord D− cells are strongly LW+ . Transient LW depression in pregnancy and some lymphomas can make a D+ person look LW− and appear to make “anti-D.” It is anti-LW.
Ch/Rg is the single most-tested HTLA. The antigens are not synthesized by the red cell ; they are C4 adsorbed from plasma . High titer, low avidity, weak fuzzy IAT, plasma neutralization (soluble C4), ficin-destroyed. Issue IAT-crossmatch-compatible or least-incompatible units. Do not call the rare-donor program for anti-Ch.
Diego earns one population fact: Dia is not a European antigen . If the stem is a South American Indigenous or East Asian mother with HDFN and a low-prevalence-looking panel, anti-Dia is in the differential with anti-Wra.
Exam traps
Treating anti-Lua and anti-Lub as equally dangerous.
Calling every DTT-destroyed antibody Kell — Yt, Do, JMH, and LW die in 0.2 M DTT too.
Calling In(Lu) a silent LU gene; it is KLF1 , and P1/In(b)/AnWj are clues.
Identifying anti-LW as anti-D because D+ cells reacted more strongly.
Sending anti-Ch/Rg or anti-Knops to a rare-donor file.
Forgetting that Lutheran is often mixed-field and weak on cord cells .